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Abstract
PTEN is a critical gene involved in the regulation of many cellular processes. The product of this gene has dual phosphatase
activity and is able to dephosphorylate the 59 end of the phosphatidylinositol (3,4,5)-trisphosphate. Within the cellular
nucleus, this protein has been associated with regulation of the expression of many genes, although the mechanism of this
regulation remains unclear. In this paper, two specific oligonucleotide aptamers were developed and selected, using the
SELEX procedure, according to their ability to detect the PTEN protein in different subcellular compartments of neurons.
While one aptamer was able to detect PTEN in the nucleus, the other recognized PTEN in the cytoplasm. The recognition
pattern of PTEN by both aptamers was confirmed using antibodies in western blots of the proteins purified from mouse
cerebellar homogenates and subcellular fractions. Additionally, we demonstrated that the two aptamers recognized
different epitopes of the target peptide. The results presented here could not be fully explained by the canonical
phosphatase structure of PTEN, suggesting the existence of different conformations of phosphatase in the nucleus and the
cytoplasm.
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Introduction
Phosphatase and Tensin homologue, deleted on chromosome
10 (PTEN) is a tumor suppressor gene that is deleted in many
human tumors and several brain disorders. By deletion of PTEN in
the mouse central nervous system (CNS), researchers have
demonstrated its role in controlling cell migration, size and
number. PTEN is also implicated in Lhermitte-Duclos disease,
macrocephaly and autism disorders in humans [1].
PTEN contains a sequence motif that is highly conserved
among the members of the protein tyrosine phosphatase family
and this enzymatic property was suspected to be responsible for
tumor suppressor activity, due to the fact that many oncogenes
induce tumoral activity by dysregulation of the tyrosine kinase
enzyme. PTEN also has phosphatase activity on phosphoserine
and phosphothreonine-containing substrates [2,3] in vitro and in
vivo [4,5]. Weak dephosphorylation of protein substrates by its
tyrosine- phosphatase activity has been observed, and few targets
have been identified. In 1998, Jack Dixon et al. demonstrated that
PTEN could dephosphorylate the acidic phospholipid, phospha-
tidylinositol-(3,4,5)-trisphosphate (PIP3) [6] . PIP3 is produced by
phosphoinositide 3-kinase (PI3K), which is important for insulin
receptor signaling pathways. These signaling pathways produce
cytoskeleton rearrangements in the inner cell membrane, driving
cell proliferation, migration, differentiation and survival [1].
Spontaneous mutations in the PTEN phosphatase domain are
oncogenic. PTEN also has a phosphatase-independent activity on
tumorigenesis, which may be more tissue-specific or associated
with a more aggressive phenotype upon loss of PTEN function [7].
Also, phenotypes caused by PTEN mutations are not completely
recovered by mutations of Dp110 or insulin signaling in Drosophila
[5], or in mouse models of mammary tumorigenesis [8], suggesting
that PTEN may have a broader role than simple antagonism of
PIP3.
In addition to its known function in the inner cell membrane,
PTEN is also found inthe neuronal nucleus[9]. Cytoplasmic PTEN
has a well known role as a negative regulator of the PI3K/AKT
pathway. It is becoming clear, however, that the role of cytoplasmic
PTENisnotthe sameasthat ofnuclear PTEN.Nuclearlocalization
of PTEN contributes to its tumor-suppressor activity in several
ways. Nuclear PTEN has a role in chromosome and cellular
stability, DNA repair, and cell cycle arrest. There is abundant
evidence implicating the nuclear protein phosphatase of PTEN in
downregulation of the mitogen-activated protein kinase pathway, as
well as cyclin D1, and in the induction of G1 cell cycle arrest. It has
also been observed at the molecular level that the regulation of p53
activity and stability by PTEN is performed via direct protein–
protein interactions, independently of its phosphatase activity
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are also found in the nucleus [12], it is possible that PTEN may be a
nuclear PIP3 phosphatase. However, a recent study suggests that
nuclear PTEN does not dephosphorylate the nuclear pool of PIP3
[13]. The mechanisms of action of PTEN in the nucleus have
remained unclear until now [9].
PTEN phosphatase activity is located at the amino terminal
domain of the protein, showing a highly conserved structure and
low antigenicity [14]. As a consequence, early observations of
nuclear PTEN were believed to be artifacts of poor quality
antibodies used in immunohistochemical staining [10]. However,
the latest immunocytological and immunohistochemical results
with newly developed PTEN antibodies have confirmed the
presence of nuclear PTEN in neurons [15] and in a variety of
normal [16,17,18,19] and tumor cells [20,21]. Despite the lack of
classical nuclear localization signal (NLS) motifs on PTEN
[19,22,23], recent studies have shown that several mechanisms
could modulate its subcellular localization. These molecular
mechanisms include a sequence for cytoplasmic localization
signaling [24], PTEN phosphorylation and involvement of Ras-
related nuclear protein (Ran)-GTPase activity [25],interaction with
major vault protein (MVP) via a bipartite NLS [9,22], mono-
ubiquitination [19], S6K-mediated export [26], and passive
diffusion [25]. Recent studies performed by Charis Eng et al. have
demonstrated that depletion of ATP results in an increase in
nuclear PTEN in various cell lines, suggesting that PTEN
subcellular localization is modulated by ATP levels [27]. Specifi-
cally, PTEN is predominantly localized in the nucleus of primary,
differentiated, and resting cells, as opposed to rapidly cycling cancer
cells, where in many cases there is a marked reduction in nuclear
PTEN [15,16,28]. Therefore, it is surmised that PTEN protein
localization may be dependent on both the cell cycle stage and the
differentiation stage. This new knowledge begs the question: which
function can be attributed to the nuclear PTEN pool?
Furthermore, molecular discrimination between the nuclear
and cytoplasmic PTEN proteins may provide an important tool to
discern the different functions attributed to the PTEN gene. An
alternative method for protein recognition can be found in a class
of ligand molecules called aptamers, from Latin ‘‘aptus’’ meaning
‘‘fit.’’ Aptamers are high-affinity ligands for a specific target, which
are selected using in vitro procedures from a combinatorial library.
Such aptamers are usually composed of oligonucleotides [29,30].
They can bind to the active site of a protein or enzyme, thereby
blocking its activity. The process of obtaining aptamers is not
restricted by antigenicity. Moreover, the nature of their phospho-
diester backbones confers high discriminant sensitivity for different
protein folding patterns [31]. Taking into account these advan-
tages, we decided to evaluate whether the PTEN protein has
different nuclear and cytoplasmic conformations through the use
of aptamer technology.
Results
Improvements on the combinatorial library of
oligonucleotides for SELEX
The most commonly used in vitro procedure for obtaining
aptamers is systematic evolution of ligands by exponential
enrichment (SELEX) [30]. The aim of our research was to obtain
aptamers that were able to recognize the native structure of PTEN
protein in histochemistry assays, and discriminate different
subcellular localizations. For this purpose, some modifications
were introduced to the SELEX procedure in order to obtain
aptamers with specific binding properties for a large number of
possible conformations of PTEN protein.
The quantity of the oligonucleotide molecules that we used
was optimized in order to maximize the amount of aptamers
available for binding to the target protein, resulting in a total of
4610
13 oligonucleotides. Quadruplicate assays were performed,
including modifications of the combinatorial library quantities
whilst maintaining the optimum number of total oligonucleotides
used for each assay. The oligonucleotide library was modified
through amplifications of random aliquots of the whole
combinatorial library, and their end effect was measured by
assessing the net amount of oligonucleotides bound to target
immobilized with nitrocellulose. Maintaining the same concen-
trations, both the control and treated oligonucleotide libraries
were incubated either with the synthetic peptide (Fig. 1)o rt h e
recombinant protein glutathione-S-transferase/PTEN phospha-
tase domain (GST-PTEN). The target protein was denatured,
placed on a 0.125 cm
2 surface of nitrocellulose membrane, and
incubated using a volume of 300 ml of oligonucleotide library in
phosphate-buffered serum-bovine serum albumin (PBS-BSA).
Quantities of bound oligonucleotides were measured by means
of real-time polymerase chain reaction (PCR), showing an
increasing number of bound aptamers after ten or more cycles.
Twenty-five cycles of PCR were used as the upper limit, as
nonspecific background amplification occurred after the estab-
lished cycle.
The results, obtained after performing the process in quadru-
plicates (Fig. 2A), indicated that the control library has substantial
background noise, showing the need for amplification. The figure
also illustrates that the number of bound oligonucleotides obtained
in the abovementioned conditions increased significantly with the
application of further cycles, although a specific correlation was
not established.
As shown in Fig. 2B, the same results were obtained using
peptide instead of GST-PTEN as a target. It was also observed
that, in comparison with GST-PTEN, the amount of bound
peptides was several magnitudes larger. The reason for the
Figure 1. Scheme of PTEN structure. A representation of the PTEN
structure (PDB: 1DR5) was obtained by means of the PyMol program.
PTEN domains corresponding to the phosphatase domain (PTPs) and
the regulatory domain (C2) are displayed in this graphical representa-
tion. The peptide selected as target was contained on the PTP domain
and was shown in blue color.
doi:10.1371/journal.pone.0018857.g001
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recombinant protein and the peptide. The smaller size of the
peptide allowed a larger amount of molecules to stick to the
nitrocellulose. When the two molecules were compared, the ratios
between size and number of bound aptamers was the same,
supporting the explanation provided above. Another interesting
observation using the peptides was a notable decrease in their
variation, caused by a difference in the methods used in the two
series of experiments. For GST-PTEN, four separate libraries
were prepared and amplified; in contrast, for the peptide, only one
library was prepared and amplified, and then split into four
separate aliquots. The latter method achieved a more homoge-
neous library, resulting in less variation.
The next step was to confirm the recognition of the GST-
PTEN by the selected aptamers obtained through targeting of the
peptides and recombinant protein. Selections were made with 10
and 25 cycles of PCR (Fig. 2A and Fig. 2B). Given that each
selection was done in quadruplicate, the selected library with the
best results was chosen. Through the use of filter binding assays,
we confirmed the specificity of the aptamers to the target protein
and the affinity of the selection. The test compared four separate
groups of aptamer libraries obtained from the previous assays.
The chosen groups are as follows: library with 25 PCR cycles
using target protein; library with 25 PCR cycles using target
peptide; library with 10 PCR cycles using target protein and
library with 10 PCR cycles using target peptide. Within each
group, four different dilutions of aptamers were used for four
filter-binding assays. As shown in Fig. 2C, it was clear that the
library obtained with 25 cycles of PCR using target peptides also
recognized the recombinant protein. That result could be
concluded from the filter binding assay with the highest
concentration of aptamers available, since there was a large
number of bound aptamers. We noted that the number of bound
aptamers decreased drastically with the dilution of the aptamer
solution, indicating that the affinity of the library was near the
range of the working dilution. Because the library was made up of
many different aptamers, this observation indicated a standard
behavior.
Finally, aptamers isolated from both selections were cloned,
sequenced and their affinities were measured by Scatchard
analysis. The affinity for the studied aptamer, PTENz7, was
found to be 75 nM as shown in Fig. 2D, and PTENz14 affinity
was 54 nM (data not shown). Other aptamers had affinities
ranging from 50 nM to 120 nM (data not shown). Thus, the
aptamers obtained through amplified libraries were specific to
GST-PTEN and showed the affinity required for our studies.
Analysis of the oligonucleotide aptamer candidates by
western blot assay
Aptamers obtained from peptides or from the recombinant
protein were cloned, and twenty of these clones were sequenced.
The specificity of each aptamer for recognition of the recombinant
protein was confirmed by dot blot assays (not shown). The results
show different oligonucleotides in the variable region with no
conserved sequence motif. These findings were in concordance
with a model containing a large diversity of products obtained
from the selection step. This is also in accord with our goal of
obtaining a large number of aptamers that can recognize a wide
spectrum of conformations, in the hope that at least one of these
recognizes the protein synthesized and modified in the cerebellum.
We proceeded to confirm that the aptamers obtained from the
selections performed with peptide also recognized the GST-PTEN
and the PTEN protein from cerebellum homogenate using
western blot assays. As shown in Fig. 3A, aptamers PTENz7
and PTENz14 were effectively capable of recognizing the
recombinant protein GST-PTEN. In Fig. 3B, the comparison
between western blots using aptamers and western blots using
antibodies developed against peptide is shown. The similar
staining patterns indicated that both the antibodies and aptamers
recognized the protein. Similar results were obtained for Fig. 3C,
where the target, from which the aptamers and antibodies were
derived, was the recombinant protein instead of the peptide. The
fact that not all the aptamers recognized the cerebellar PTEN
protein in western blot assays was perhaps a consequence of its
post-translational modifications. The design importance of the
potential structures that the aptamers can take is shown in
Fig. 3D. All structures form the double helix hairpin in the
‘‘constant region of the primers’’, which is the region involved in
providing molecular stability to the aptamers. The resulting
structures of the aptamers (obtained through mFOLD, http://
www.idtdna.com/Scitools/Applications/mFold) are in concor-
dance with those shown in Fig. 3D.
Analysis of the aptamer recognition properties of PTEN in
histochemistry assays
Special care was taken with the brain fixation for histochemistry
assays, using non-crosslinking fixation to avoid denaturing the
protein. An ethanol - acetic acid mixture (95%:5%) was chosen,
because Carnoy’s fixative and, more generally, ethanol-based non-
crosslinking fixatives have been reported [32] to allow a
satisfactory preservation of the antigenicity of proteins and their
epitopes in tissues [33,34]. It may be advantageous to investigate
the native distribution of cellular and extracellular components
Figure 2. Aptamer’s selection using PTEN recombinant protein and PTEN synthetic peptide. A. In these assays, selected oligonucleotides
were separated from the GST-PTEN target, indicated above the graph, and quantified by means of real-time PCR. The effect of amplification of the
library on the quantity of oligonucleotides obtained is illustrated in this graph. The number of molecules, as indicated on the y axis, is obtained
through extrapolation of the standard curve, while the number of cycles applied to the library used is indicated on the x axis. The three assays show a
significant increase compared with the library without amplification, used as control. Libraries were amplified through PCR separately for each assay.
Standard deviation is indicated using bars on each column. B. Results for assays as described above, using the synthetic peptide of PTEN as target,
instead of GST-PTEN. Libraries were separated in aliquots from a larger pool that was amplified through PCR. C. Specificity of the oligonucleotides
obtained. Aliquots of the selected oligonucleotides were amplified again through PCR, separated, and split into four dilutions. The filter binding
assays were performed with different concentrations for four separate selections of aptamers, and each selection is indicated at the bottom of the
graph. The gradient of concentration follows the slope of the triangle and the standard deviation is indicated using bars on each column. D. Affinity
of the aptamers obtained. Autoradiography of radioactive aptamers bound to specific targets. The aptamer PTENz7 recognized the recombinant
PTEN protein and the peptide without binding to the GST-Anp32e recombinant protein in filter binding assays. E. Selected oligonucleotides
developed with 25 cycles of library amplification, using the synthetic peptide of PTEN as target, were cloned into vectors and sequenced. Plasmids
from six different clones were labeled by PCR containing ATP-gamma-
35PO4, incubated, and their affinity was measured in Scatchard binding assays.
The example shown is the oligonucleotide from clone PTENz7, and the affinity constant measured corresponds to 75 nM, using GST-PTEN protein at a
final concentration of 25 mM. At the bottom of the graph the autoradiographic results from the radioactive aptamers retained in the filter binding
assays are shown. The concentration of the aptamers used corresponds to the measurements illustrated within the graph. On the x axis, the
concentration of PTENz7 in nM is provided. On the y axis, the ratio between bound and free aptamers is shown.
doi:10.1371/journal.pone.0018857.g002
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target ligand [35]. Under these conditions, the ‘‘naive’’ PTEN was
analyzed in histochemistry assays using the selected aptamers, and
subcellular localization was observed in detail (Fig. 4).
The two aptamers, designated PTENz7 and PTENz14, were
selected according to the following properties: i) The aptamers
recognize the same known antigen site of the protein; ii) The
aptamers recognize the recombinant and the native PTEN protein
whether in a denatured or naive conformation; and iii) The
aptamers discriminate nuclear from cytoplasmic PTEN in
histologic assays.
The properties analyzed for some aptamers are summarized in
Table 1.
Specificity of the aptamers PTENz7 and PTENz14
evaluated by histological assays
The potential artefact of the aptamer staining pattern in the
histologic samples was further evaluated through the use of
different controls. PTEN recognition was demonstrated by
incubation of the oligonucleotide aptamers developed with the
synthetic peptide and with the recombinant protein PTEN. The
recombinant protein competed with the native PTEN protein for
the aptamers, PTENz7 and PTENz14, resulting in a decrease in
histologic staining (Fig. 5). The presence of the recombinant
protein did not affect the staining properties of the aptamer used as
control (Anp32a protein). The positive results of this control
confirm that the blockage of the aptamers depends on the
sequence motif and not on some nonspecific interaction between
the DNA and the recombinant protein.
In advance, we had developed a rabbit antiserum against the
same synthetic peptide of PTEN [36]. Thus, a control of the
aptamers’ specific recognition of PTEN within the tissue could be
achieved by masking the specific antigen using this antiserum.
Histologic samples were pre-incubated with the antiserum and
during the incubation with the aptamer. As expected, the staining
was poor or absent in the antiserum-treated histologic samples
incubated with PTENz7 aptamer, a fact that demonstrates the
specificity of the target recognition by the aptamers.
Figure 3. PTEN recognition in Western blot assays and predicted PTEN aptamer conformations. A. Protein pattern expression in E. coli of
the recombinant proteins GST (E. coli) and GST-PTEN (+PTEN) in conjunction with the affinity column-purified proteins (GST and +PTEN). The identity
was confirmed by binding of the goat antibody (Ab), resulting in similar patterns to the cloned aptamers derived from peptide (PTENz7 and
PTENz14). B. Western blot using aptamers PTENz7 and PTENz14 (z7 and z14) and antibodies (Ab Rb) developed with peptide in the cerebellar
homogenates. The synthetic aptamer strand of Anp32e was used as a negative control, as well as the omission of aptamers (–). The arrow indicates
the most intense band corresponding to the 55-kDa PTEN isoform. C. Western blot detection made as in (B) using aptamers and antibodies
developed against the GST- PTEN recombinant protein. The arrows indicate the band of 55 kDa and two bands of greater size, possibly due to
ubiquitin-modified PTEN. D. PTEN aptamer conformations: Sequences from PTENz7 (left column) or PTENz14 (right column) were analyzed for internal
interactions and the best three predicted structures (mFOLD, http://www.idtdna.com/Scitools/Applications/mFold) were presented in this panel. For
the more stable conformation of PTENz7, a differential free energy of Gibbs of 219.04 kcal.mole-1 was observed and for PTENz14 this value was
217.3 kcal.mole-1.
doi:10.1371/journal.pone.0018857.g003
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where no alterations of the staining pattern were observed. There
are two possible explanations for that finding. The first possibility
is that the aptamer recognizes another epitope from within the
same antigen of the antiserum, and antibodies are thus unable to
block the aptamer–PTEN interaction. The second possibility is
that the aptamer recognizes a protein other than PTEN, so the
antiserum would produce no detectable changes in the staining
pattern.
PTENz7 and PTENz14 recognize different epitopes from
the same antigen peptide
The results presented show that the aptamers PTENz7 and
PTENz14 recognize the peptide and the recombinant protein in
solution or in the nitrocellulose membrane. This leads us to
consider the possibility that the rabbit antiserum is incapable of
recognizing the entire peptide used as target. The peptide consists
of 14 amino acids, and the adequate length for antigen
presentation is about 7–8 mer [37]. Therefore, there are two
possible epitopes. It is plausible that, as a consequence of protein
conservation during evolution [10,14], the antiserum recognizes
only one portion of the antigen, while the other portion of the
peptide is non-antigenic.
To test the hypothesis of incomplete recognition of the peptide
by antiserum, a specific experiment was performed. If the
hypothesis was correct, the antibody would be able to bind to
the peptide, hiding the epitope of the aptamer PTENz7, while the
aptamer PTENz14 would bind to the other free epitope. Through
co-purification of the double-bound peptide, the aptamer
PTENz14 and the antibody would precipitate. If the levels of
the peptide were increased, the proportion of aptamers measured
would increase above the background level. If the recognized
epitope was blocked by the antibodies, the aptamers would be
unable to bind to the peptide and so would leave the
oligonucleotides’ background unaltered. The bound aptamer
molecules would then be easily detected by means of real-time
PCR (Fig. 6). The results obtained with the assays of co-
purification were consistent with the model of incomplete
recognition and explained the lack of interference of the antiserum
in tissue staining with aptamer PTENz14.
Figure 4. PTEN aptamers and PTEN detection in cerebellar histologies. Staining pattern in histologic samples of mouse cerebellum at two
magnifications, 1006and 10006, as indicated at the top of each column. To the left of each pair of panels the aptamer or antibody utilized for the
histological staining assay of the PTEN protein was denoted. The layers of the cerebellum are indicated within each illustration as internal granular
layer (IGL), Purkinje cell layer (PcL) and molecular layer (ML). The Purkinje cells are shown at the highest magnification, 10006, where nuclear (N) or
cytoplasmic (C) localization is distinguishable. The known aptamer Anp32e (Anp) was used as a positive control. The patterns belonging to clones 3,
4, 5, 6 and 9 corresponded to the aptamers developed against the recombinant protein GST-PTEN, while the patterns associated with z7 and z14
were the aptamers PTENz7 and PTENz14 developed against the peptides.
doi:10.1371/journal.pone.0018857.g004
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using aptamers and antibodies
If the recognition of PTEN by each aptamer differs due to an
alternative conformation of the native protein, then the histolog-
ical staining pattern with each aptamer – given that the protein is
denatured by the heating of the tissue required for antigen
retrieval (AR) – is expected to be similar. We observed that, after
the denaturation of the protein, histological assays of PTENz7 and
PTENz14 effectively resulted in the same staining pattern (Fig. 7).
Using crosslinking fixation with paraformaldehyde, nuclear
staining for both aptamers was absent from the granule cell nuclei
and instead colocalized in the mossy fiber synapses. Nuclear
staining of the Purkinje cells was restricted to the PTENz7
aptamer, whereas the PTENz14 aptamer was relegated to the
cytoplasm, with granular colocalization of PTENz14 and PTENz7
remaining within the Golgi system. Nuclear staining of the granule
cells was unmasked when the AR technique was applied to these
tissues, and resembled the colocalization results obtained with AR
in alcohol/acid fixations. The lack of staining in the Purkinje cells
was observed using both kinds of fixations, and could possibly be
attributed to the fact that the proteins became soluble and were
eluted from the tissues.
The nature of PTEN localization in the nuclei can be
attributed to binding by one ubiquitin modification, which also
produces a delay in electrophoretic mobility. We therefore
analyzed for PTEN isoforms in a gel electrophoresis assay using
a polyclonal antibody against the carboxy domain and subcellular
fractionations. The results obtained using overexposure of the
western blots showed the presence of one ubiquitin modification
in the nuclear fraction and two ubiquitin modifications in the
cytoplasmic fractions. Comparisons between aptamer and
antibody staining in western blot assays are presented in
Fig. 7C. In this figure, we show that either aptamer was able
to recognize PTEN with the ubiquitin modifications, and that this
is not the cause of the subcellular discrimination of the aptamers.
Note that the intensity of the band corresponding to PTEN
without ubiquitin was diminished in both aptamers. It could be
possible that neither aptamer recognizes all isoforms of PTEN. As
further proof that the selected aptamers were capable of
recognizing the native protein, we used ‘‘immunoprecipitation’’
assays, presented in Fig. 7D. PTEN was purified from a
homogenate protein solution with the selected aptamers. The
presence of PTEN was verified through the use of goat antibodies
in western blot assays, confirming that each aptamer was able to
recognize naı ¨ve PTEN in its native conformation. Through an
assay with the control aptamer (Anp32) that does not recognize
PTEN it can be concluded that the PTEN protein does not
display nonspecific interactions with the purification reagents.
These results were further supported by interpretation of
subcellular fractionation assays and the ability of each aptamer
to deplete PTEN specifically from each of the nuclear and
cytoplasmic fractions. Taking these findings into account, the
aptamers, recognizing different extremes of the peptide sequence,
could differentiate protein localized by histological staining or in
subcellular fractions. Due to the fact that the peptides were
partially included in the phosphatase structure described, these
results reinforce the existence of a new conformation of PTEN,
different from the known phosphatase conformation that is
present in the neuron.
Discussion
The results presented here showed, for the first time, a different
conformation of the amino domain of the PTEN protein in neuron
nuclei. Since we did not detect the phosphatase conformation, it is
appropriate to surmise that PTEN has a non- phosphatase
function in the nucleus.
Our findings are consistent with recent nuclear PTEN studies,
which also suggest a non-phosphatase role of this protein, such as
regulation of p53 structure and function through direct protein–
protein interaction free of phospholipase activity [11,38]. Further-
more, the latest research demonstrates that PTEN does not
influence the dephosphorylation of the PIP3 nuclear pool [13].
Another finding supporting our hypothesis has been described
by Goberdhan et al., in which Drosophila phenotypes produced
by mutations of PTEN are not entirely offset by Dp110 mutations
[5].
Also, on a technical note, the results presented here show an
improvement on the SELEX method [39]. The oligonucleotides
obtained with this procedure have high affinity and specificity for
the PTEN protein or a chemically synthesized peptide used as
target. In contrast with other improvements on the SELEX
method, which use a greater number of selection steps with the
native protein [40,41] or the recombinant protein [42], we used a
single-selection step with a preset amplification of the library.
Although it reduces the number of selection steps of the process,
our improvement on the SELEX method does require evaluation
of a greater number of clones to obtain the aptamer with the
desired properties.
There is a large body of evidence suggesting that more
aggressive cancers are linked to the absence of nuclear PTEN in
patients [16,17,21,43,44,45] Thus, nuclear and cytoplasmic
detection of PTEN using aptamers and antibodies could be an
important indicator for clinical prediction. Our goal was to obtain
aptamers that were able to discriminate between nuclear and
cytoplasmic localization of PTEN, while giving priority to those
directed at a known target sequence.
Unexpectedly, the differential recognition of the nuclear and
cytoplasmic isoforms of PTEN was due to the recognition, by the
aptamers, of different regions of the peptide. The manner in which
different epitopes of the peptide were displayed was determined by
different conformations of the amino domain of the PTEN protein
(Fig. 8).
Table 1. Aptamer’s properties for PTEN protein detection.
Aptamer Western blot Histology Cellular localization
Clone 3 ++ + Nuclear
Clone 4 ++ Cytoplasmic
Clone 5 ++ + Nuclear
Clone 6 2 + Nuclear/Cytoplasmic
Clone 7 + 22
Clone 8 + 2 Nuclear
Clone 9 ++ Nuclear
PTENz7 + +++ Nuclear
PTENz14 + +++ Cytoplasmic
Properties measured in the aptamers derived from peptides (PTENz7 and
PTENz14) and cloned aptamers derived from the recombinant protein GST-
PTEN (Clone 3, Clone 4, Clone 5, Clone 6, Clone 7, Clone 8 and Clone 9). The
columns: western blot, histology and cellular localization show the performance
of each aptamer for the corresponding assay and their subcellular localization.
Aptamers PTENz7 and PTENz14 are recognized as the best choice considering
their ability to recognize the native protein PTEN, their well-defined localization
and different manifestations in subcellular regions.
doi:10.1371/journal.pone.0018857.t001
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neuron cell cultures, ubiquitin was found in the PTEN protein of
the nucleus and two ubiquitins were found in the 13 and 124 amino
acids of PTEN [46]. Our results describe for the first time the
existence of both isoforms of ubiquitin-modified PTEN as stable
proteins in the nucleus and cytoplasm of cerebellar neurons. Our
aptamers showed greater preference for the ubiquitin modified
PTEN than the non-ubiquitin modified PTEN in western blot
assays. Precipitation assays showed the ability to precipitate the
majority band, but not all of the protein present was depleted.
Recent studies demonstrate the effect of ATP on the localization
of nuclear PTEN. The authors found two sites of ATP binding
that correspond to the 60–73 and 122–136 amino acids of the
phosphatase domain [47]. Our target region, corresponding to the
31–43 amino acids of the second beta-sheet of the same domain
and, as in ATP domains, 60–73 and 122–136, presented only a
small region exposed to the surface with a large part in the inner
structure of the phosphatase. A change of conformation of this
structure was expected for a switch of the PTEN localization and
function into the nuclear environment (Fig. 8).
One part of the utilized peptide is recognized by rabbit
antibodies and the other part of the peptide has the capability of
being recognized only by one of the aptamers. According to these
results and assuming that the aptamers recognize both extremes of
the peptide, one of them must be located internally in the protein
structure. For this internal extreme to be exposed and detectable
by the aptamer, the protein would have to be open or with a fold
different to the description for the structure of the phosphatase.
Our hypothesis that there exists a relevant structural change which
establishes the exposure of different regions of the PTEN protein is
also supported by the discoveries of the group of Dr Eng [27,47].
Such results, obtained by means of the mutational analysis of
Figure 5. Specificity of PTEN staining in cerebellar histologies. The PTEN staining pattern using aptamers analyzed in cerebellar slices from
mice. PTEN was detected with the peroxidase system within the cerebellar cortex of adult mice using the selected aptamers and a positive aptamer
control developed from a peptide contained within the Anp32e protein sequence. The aptamer used is indicated in the column heading, while the
designated treatment with recombinant proteins or antibodies is mentioned to the left of the rows. The first row shows the histological staining
without any competition for the aptamers. The second row indicates aptamers pre-incubated with the recombinant protein before and during the
histologic assay. The third row shows histologic samples where aptamers were pre-incubated before and during the histological assays with rabbit
antiserum developed against the PTEN peptide. The cerebellar cortex layers are indicated in each micrograph as: Molecular layer (ML); Purkinje cell
layer (PCL); Internal granular layer (IGL). Images were obtained at 1006magnification. The subcellular localizations are shown in the upper circle of
each aptamer staining in the control row.
doi:10.1371/journal.pone.0018857.g005
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interact if the PTEN protein adopted a different shape to the
structure of phosphatase classically described. Moreover, the
results presented by Lindsay et al, 2006, which demonstrate the
lack of mobilization of nuclear IP3 in the presence of PTEN,
would point towards a role different to that of phosphatase for this
protein. In conclusion, the best explanatory model for our results
and those previously published would be the occurrence of a
substantial structural change of the PTEN protein, which would
preclude its activity as phosphatase and would establish the
existence of a role not previously described for this tumor
suppressor.
Materials and Methods
Peptides and proteins
Thetargetsused werePTENpeptide,Anp32 peptides,and GST-
PTEN (amino terminal domain) of 40,000 Daltons. Synthetic
peptides, including the sequence corresponding to amino acids 33–
47 for human and mouse PTEN phosphatase (33-IAMGFPAER-
LEGVYR-amide-47, show in the Figure 1), were commercially
obtained at an HPLC purity of 70–85% (antigen grade Alpha
Diagnostic International, Inc., San Antonio, TX USA). The DNA
encoding human PTEN phosphatase amino-terminal domain was
obtained by PCR, cloned, then sequenced in the expression vector
pGEX2T (Amersham Pharmacia Biotech, NJ, USA). Protein was
obtained by transformation of Escherichia coli, and its expression was
induced using isopropyl thiogalactoside. Pure proteins were
obtained using a glutathione-Sepharose column (Glutathione
Sepharose-4 fast-flow, Amersham Biosciences, Uppsala, Sweden).
Aptamer design and selection
Library construction. An 87-nucleotide synthetic DNA
composed of 21 and 16 nucleotides flanking a ‘‘variant region’’ of
50 random nucleotides (59-CGGAATTCCGAGCGTGGGCGT
(N)50 TACGCCCACGCTCGAG-39 (87 mer)), was generated and
purified by HPLC (Integrated DNA Technologies Inc., Coralville,
IA, USA). This target sequence was amplified using primer 1: 59-
CGGAATTCCGAGCGTGGGCGT-39 (21 mer), and primer 2:
59-CTCGAGCGTGGGCGTA-39 (16 mer). Biotin was used to
label the primers at the 59- ends (Integrated DNA Technologies
Inc., Coralville, IA, USA). The extremes of the constant sequence
(underlined in the library sequence) of the aptamers were
complementary, capable of producing a double helix of 13 bases.
The variable region was where the binding was expected to take
place. Each tube contained 100 ml of PCR mixture with 4.2 pmoles
(400 nM) of combinatorial library, containing approximately
4.0610
13 different molecules. The PCR mixture (Tris 10 mM
pH 9 at 25uC, KCl 50 mM, Triton X-100 0.1%, dNTP 1 mM,
MgCl2 1.5 mM,eachprimerat1 mM)wascycledat94uCfor30 sec
in the denaturing step, at 58uC for 30 sec in the annealing step, and
at 72uC for 10 sec in the elongation step. Cycle numbers are
indicated in each experiment. Double chain products of PCR were
separated by heating at 95uC (5 min) and then cooled with two
volumes of PBS/3% of BSA and maintained on ice until use.
Target presentation. The phosphatase domain is the most
highly conserved region of the PTEN protein and was chosen as
the target for aptamer selection. Two regions of the phosphatase
were used as sequential epitopes of the target: one a synthetic
peptide comprising the 33–47 residues of PTEN and the second
the entire amino terminal domain of human PTEN (200 amino
acids) in recombination with the carboxy terminal of the
glutathione-S-transferase (GST-PTEN). This target was
denatured previously to be used for oligonucleotide selection, in
order to obtain sequential epitopes from the protein.
Both targets, peptides and proteins, were presented on a
physical support of nitrocellulose to allow interaction with the
single-strand library of oligonucleotides. The membrane contain-
ing the target protein was incubated with 200 ml of PBS containing
2% BSA and 100 ml of single strands of the PCR amplified library
(1:2) overnight at 4uC or otherwise for 3 hours at room
temperature.
Partition of the bound oligonucleotides. After target
presentation, the bound aptamers were separated from the
mixture by washing the nitrocellulose support in 2% BSA-PBS
(500 ml) three times for 15 minutes, followed by three 15-minute
washes in PBS.
Elution. The bound DNA was separated from the target
proteins captured on the nitrocellulose membrane (0.125 cm
2)
using 100 ml of milliQ-filtered water, and heating at 95uC for 3–
5 min. The eluted DNA was then transferred to another tube, and
5 ml was used as a template for PCR. The mixture and the clones
of each aptamer obtained were analyzed by dot blot assay to
confirm the target recognition, using the recombinant GST-amino
terminal of PTEN protein or the synthetic peptide.
Dot blot assays
Aptamers with little or no cross-reactivities between the two
proteins were identified and selected for use in further studies.
Dot blot assays with the aptamers were performed as follows:
200 ng of peptide and 2 mg of recombinant protein GST-PTEN
were seeded as drops in a nitrocellulose membrane strip
(PROTRAN
TM; Schleicher & Schuell Inc., Keene, NH), dried
and blocked with PBS-BSA 2% prior to the incubation with
1.5 ml of 0.5 mM oligonucleotides in a plastic tube. The 59-biotin
of the oligonucleotides was developed with an alkaline phospha-
tase system.
Figure 6. Simultaneous recognition of PTEN peptide by
aptamers and antibodies. The results of precipitation are shown in
terms of net amounts of molecules acquired through extrapolations
from the standard curve of quantification. The backgrounds considered
(PTENz7 and PTENz14) were attained through incubation and co-
purification of the aptamers and antibodies in the absence of peptides.
Quadruplicate samples showed the positive binding of PTENz14 to the
peptide (PTENz14+Peptide). Findings also confirmed the blockade of
PTENz7 recognition by the antibodies (PTENz7+Peptide). Extrapolations
from the standard curve of quantification show 1.8610
11 molecules of
PTENz14 aptamer were bound to the peptide and co-precipitated with
the antibodies attached to Sepharose – nearly a 20-fold increase with
respect to the background (P,0.0001).
doi:10.1371/journal.pone.0018857.g006
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Quantification of ligand-bound DNA molecules was performed
with real-time PCR using the ABI Prism 7500 Sequence Detection
System (PE Applied Biosystems, Foster City, CA, USA). PCR
analyses were performed in 50 ml reactions with SYBR Green dye
(PE Applied Biosystems) and ROX dye as an internal fluorescent
reference (Molecular Probes, Invitrogen, Carlsbad, CA, USA).
None of the primer sets used gave a signal (CT.25) in control
reactions without templates. Standard curves between 10
9 and 10
5
copies were determined for the primer set by dilution of input
DNA. The inverse and complementary sequences of primers (13
bases) contained in the library structure were expected to interfere
in the efficiency of the polymerase amplification. The synthetic
PTENz14 aptamer was used as a template, yielding a slope close to
the theoretical value for amplification per cycle (Ct=23.364 *(log
C0)+43.909; R
2=0.983 Efficiency=98.266%). The number of
aptamers in the input was calculated from the cycle thresholds (CT)
for each primer set by extrapolation with the standard curves
made using 7500 System Software (Applied Biosystems, Foster
City, CA, USA).
Radioactive labeling of aptamers
Ligands were labeled by adding 1 mlo f[
32P]-dCTP (3,000 Ci/
mmole, Amersham Biosciences, UK) to 100 ml of mixture used in
the PCR (10 mCi or 370 kBq). The PCR products were separated
from the free nucleotide [
32P]-dCTP using size exclusion G-25
columns (MicroSpin S-200 HR columns, Pharmacia Biotech,
USA). Approximately 2.5610
6 cpm was incorporated at 1 mM
concentration for each 50 ml of PCR reaction.
Filter binding assay. Nitrocellulose membranes were used
to quantify the ligand-receptor complexes formed between the
selected oligonucleotides amplified by PCR and the pure protein
at a constant concentration of 0.5 mg/ml. The mixture was
incubated for 1 h in a final volume of 40 ml with 50 mM Tris
Figure 7. Antigen retrieval and PTEN detection in cerebellar subcellular fractions. A. No crosslinking fixation. Histologic samples showing
the peroxidase staining pattern of denatured proteins. 1006and 10006magnifications are indicated at the top of each column. The denaturation
was achieved through heating of the tissue, a technique commonly known as antigen retrieval (AR). The aptamer utilized for the staining is indicated
on the left of each row. The cerebellar cortex layers are indicated in each micrograph as: molecular layer (ML); Purkinje cell layer (PcL); internal
granular layer (IGL). The micrograph at 10006magnification indicates Purkinje cells (Pc) and granule cells (Gc). B. Crosslinking fixation. Histologic
samples fixed with paraformaldehyde (PFA) with and without antigen retrieval (+AR and -AR respectively) were stained simultaneously with PTENz7
(CY3-red) and PTENz14 (FITC-green). Colocalization was observed as yellow labeling at 4006magnification. C. Western blot subcellular fractions and
homogenates. Homogenates and subcellular fractions were developed using a polyclonal antibody against the carboxy terminus of PTEN.
Cytoplasmic fraction presented a large amount of PTEN, corresponding to the 55-kDa band. Another band of 120 kDa was also observed in this
fraction (duplicates). The nuclear fraction presented a major band of 55 kDa with two minor bands of 80 kDa and 40 kDa. In homogenates, the major
band of 55 kDa was observed (Ab), but required overexposure (Ab+) to detect the modified-mobility isoforms. The band of 55 kDa had a lower
intensity than the antibody band. Both aptamers PTENz7 (z7) and PTENz14 (z14) detected the 80-kDa and 120-kDa bands. Controls were put in place
using the negative chain corresponding to the lysozyme aptamer (Liso). D. Immunoprecipitation assays. Proteins from cerebellum homogenate were
utilized to purify PTEN by means of the aptamers PTENz7 and PTENz14. The aptamer Anp32 was used as a negative control for the purification. The
purified proteins were separated in denaturing 10% SDS-PAGE, transferred to a nitrocellulose membrane and detected using goat antibodies against
GST-PTEN protein. Corresponding aptamers are indicated above each western blot lane, while the molecular weight is denoted to the left of the
image. The PTEN protein was precipitated from the subcellular fractions and the presence of the protein was analyzed in the supernatants. Note that
PTENz7 was able to diminish the PTEN staining from the nuclear fraction, whereas PTENz14 affects the cytoplasmic fraction.
doi:10.1371/journal.pone.0018857.g007
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unbound species could be removed by three repeated washes with
250 ml of PBS. The bound oligonucleotide chains were then
quantified using real-time PCR and detected by radioactivity using
a PhosphorImager screen (Amersham Pharmacia Biotech, NJ,
USA). The retained radioactivity was cut off and measured in a
liquid scintillation counter (Beckman).
Ligand oligonucleotide cloning and sequencing
PCR amplification (up to 25 cycles) was applied to 5% of the
eluted single-stranded DNA from the nitrocellulose membrane.
The 87-bp products from PCR were cloned into an E. coli pGEM
vector (Vector-T Easy system, Promega Corporation, Madison,
WI, USA) and sequenced. The pure plasmid was used as a PCR
template (20 ng) using modified primers.
Aptamer sequences
PTENz7: 59-CGGAATTCCGAGCGTGGGCGTGGTCAT-
ACCGCGCCTATCGAACTCGCCA-CTCGCGTGCAGCTC-
TGTGTAGGTACGCCCACGCTCGAG-39
PTENz14: 59-CGGAATTCCGAGCGTGGGCGTGAGCC-
CTAAACACAAGTCCGCAGGGGT-GTGGTAATATTCGC-
AGTTGTGTGTACGCCCACGCTCGAG-39
Scatchard analysis
Affinity of ligands for a specific target was determined using the
radiolabeled oligonucleotides from the filter binding assays, and
the radioactivity was measured with a Beckman scintillation
counter. The results obtained for aptamers, mixtures, or clones
were used to perform a Scatchard analysis (Prism 4 program from
http://www.graphpad.com/prism/Prism.htm).
Experimental animals
Mice of the inbred strain Kcnj6wv B6CBACa Aw-J/A-Kcnj6wv
were obtained from Jackson Laboratories (Bar Harbor, ME, USA),
and were raised at the Institute of Biotechnological Research,
National University of San Martı ´n, Argentina. All experiments
were performed in triplicate using adult animals. Animals were
sacrificed by decapitation. All animal procedures were performed
according to the rules and standards of animal protection laws and
the regulations for the use of laboratory animals of the National
Institutes of Health, USA. This paper has been evaluated and
approved by the Ethics Committee of the Hospital de Clı ´nicas of
the University of Buenos Aires, as stated in report number 0298/
10 dated April 23rd 2010.
Antibodies
Commercial antibodies were used to detect the carboxy
terminal end of PTEN (human or mouse origin) (1:50 for
histology, clone 6H2.1, Cascade, MA, USA), the amino terminal
end of PTEN (PTEN N-19 sc-6818, goat polyclonal, Santa Cruz
Biotech., CA) and rabbit carboxy terminal (1:400) (PTEN C-20 sc-
6817-R Santa Cruz Biotech., CA). The PTEN antiserum against
the peptide, previously developed in our laboratory, was diluted
with PBS-BSA 2%, 1:50 for immunohistochemistry and 1:400 for
western blot as described Perandones et al 2004 [36].
Western blot
Tissues were dissected and homogenized in 1:10 w/v of radio-
immunoprecipitation-assay buffer (RIPA) (Tris-HCl 50 mM, pH:
7.5, NaCl 150 mM, Nonidet P40: 1%, deoxycholate: 0.5% and
SDS 0.1%). Fifty micrograms of protein was loaded in each lane of
a 10% SDS-PAGE gel. The nitrocellulose membranes with the
transferred proteins were blocked with PBS-BSA 2% and
incubated with antibodies or the oligonucleotides containing
biotin label. The antibodies were revealed using alkaline
phosphatase linked to secondary antibodies, and the oligonucle-
otides were revealed using avidin-alkaline phosphatase (Promega
Corporation, Madison, WI, USA) or peroxidase systems, as
indicated. PTEN amino terminal rabbit polyclonal antibodies
were diluted 1:400 with PBS-BSA 5%. A monoclonal anti-rabbit
gamma chain-specific antibody coupled to alkaline phosphatase
(dilution 1:10,000, Clone RG-96, purified antibody, Sigma Co.,
St. Louis, MO, USA) was used in western blots and developed
Figure 8. Scheme of PTEN structure showing the selected PTEN peptide and the ATP-binding regions. The figure shows the regions of
interest: the amino domain of the PTEN protein surface and the backbone. The peptide surface exposed on the PTP domain is shown in the peptide
sequence (detailed in the upper left hand corner). The ATP binding regions are shown in blue, and the target peptide is shown in red as shown in the
upper sequence. Note that the ATP binding peptides correspond to the internal portion of the phosphatase structure. The graphic was developed
using the PyMol program.
doi:10.1371/journal.pone.0018857.g008
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blue tetrazolium. A commercial goat antibody against PTEN
amino-terminal protein was used as a control (dilution 1:500, sc-
6818, Santa Cruz Biotech., CA, USA) and developed with anti-
goat IgG coupled with alkaline phosphatase (dilution. 1:1000, anti-
goat IgG-AP, sc-2022, Santa Cruz Biotech., CA, USA). The
carboxy domain of PTEN antibody was used in western blot of the
subcellular fractionation for measurement of PTEN and developed
with a secondary antibody and a chemiluminescent substrate for
peroxidase (SuperSignal H, Thermo Fisher Scientific, USA).
Histochemistry
Wild-type mouse cerebella were dissected at different postnatal
ages, fixed in alcohol/acetic acid (95%/5%) or paraformaldehyde
(4%) as indicated, embedded in paraffin, sliced, and mounted on
silanized glass (Silane, Sigma Co., St. Louis, MO, USA). The
paraffin was removed from the slice and tissues were incubated
overnight at 4uC with one of the following: rabbit/goat polyclonal
antibodies, or mouse monoclonal antibody or aptamers. Then
excess molecules were rinsed away twice with PBS, and developed
for 1 h using avidin-peroxidase (1:10,000, Thermo Fisher
Scientific Inc., IL, USA) or secondary antibodies coupled to
peroxidase or synthetic aptamers labeled with Cy3 and FITC
fluorochromes. After 1 hour of incubation, the avidin excess was
removed by three washes of PBS, and later the peroxidase was
developed with di-amino-benzidine 8% w/v, H2O2 0.3% v/v in
PBS buffer. Images were obtained using a BX-60 Olympus IX-71
microscope (Olympus, Japan), digitized with an Optronics camera,
and images were merged using the programs Image-J-Pro 4.0 or
the Adobe PhotoShop program.
Comparisons of histologic samples with different
aptamers
After blocking the slices, they were incubated overnight at a
temperature of 4uC with aptamers containing biotin obtained
through PCR. After the amplification, the mixture was heated for
3 minutes to 94uC and then quickly cooled to 4uC by diluting the
solution with 2 volumes of cold PBS-BSA 5%. The cold
temperature stabilizes the double helix in the solution, formed
by the constant sequence of aptamers. Where the synthetic
aptamers containing biotin, PTENz7 and PTENz14 (1 mM), were
used, the slices were incubated in PBS-BSA 5% for 3 hours at
room temperature. As a negative control, slices were incubated
with a polyclonal antibody (1:1,000 in PBS-BSA 5%). A positive
control was established using a synthetic aptamer that recognizes
protein Anp32e (1 mM).
Competition with recombinant protein
Histologic samples similar to the ones described above were co-
incubated with the aptamers containing biotin (250 nM) and the
recombinant protein GST-PTEN (525 mg/ml) for 3 hours at room
temperature. As a positive control, slices were incubated with
250 nM of PTENz7 or PTENz14 in PBS-BSA 5% without
competition. Finally, the control of the competition with GST-
PTEN was carried out using the synthetic aptamer containing
biotin that recognizes the protein Anp32a.
Blocking with antibodies. In order to better demonstrate
the specificity of the aptamers towards phosphatase PTEN,
competitions with antiserum from rabbit immunized with
recombinant PTEN were performed. After removing the
paraffin and blocking the slices with PBS-BSA 5%, they were
incubated overnight with the rabbit antiserum and BSA separately
in a humidity chamber at 4uC. The pre-incubated slices were
incubated with the synthetic aptamers containing biotin for
3 hours at room temperature, again in a humidity chamber.
After incubation, 3610 minute washes were performed with PBS.
The aptamers were revealed as described above.
Competition assays between aptamers and antibodies
for recognition of the PTEN peptide
To determine the antigenicity of the epitopes recognized by
each selected aptamer, a union assay between aptamers, antiserum
and the peptide was carried out in solution in quadruplicate.
A) Antibody preparation. An 800 mg sample of protein A
coupled to Sepharose (Sigma-Aldrich, USA) was incubated with
2.8 mg of complete proteins obtained from peptide-immunized
rabbit serum, in PBS solvent in a final volume of 130 ml. Once the
incubation time had elapsed, the solution was centrifuged for
1 minute, ultimately discarding excess supernatant. In order to
wash out the immunoglobulin that failed to attach to protein A,
the Sepharose beads were washed three times in 130 ml PBS for
5 minutes at room temperature and centrifuged. The pellets were
suspended in 130 ml PBS-BSA 1% and afterwards divided into
aliquots.
B) Attachment of antibodies to peptides. The aliquots
were incubated with the peptide (3 mM) at room temperature and
agitated for 1 hour to allow the union of the immunoglobulins.
Next, a 10-second centrifugation was performed, excess
supernatant was discarded and three washes with PBS were
completed. Both mixtures, the incubated and the non-incubated
peptides, were divided into 2 aliquots each.
C) Assays of aptamer union. Each sample containing the
Sepharose bead aliquots was incubated with each synthetic
aptamer, PTENz7 and PTENz14 (1 mM), separately. The
incubation took 1 hour at room temperature with gentle
agitation. Each sample was washed three times with 500 mlo f
PBS following incubation and the bound aptamers were eluted
using 20 ml of NaOH 0.15 M, neutralized with 20 ml of HCl
0.15 N.
D) Quantification of the eluted aptamers. The
quantification of the aptamers obtained was performed by real-
time PCR, as described above in the section on Aptamer
Selection. From each aptamer sample 2 ml aliquots were
quantified, in quadruplicate, using 35 cycles at 94uC for 30 sec
in the denaturing step, at 58uC for 30 sec in the annealing step,
and at 72uC for 10 sec in the elongation step.
Antigen retrieval
Paraffin was removed from the slices, which were later hydrated
in citric acid (10 mM pH 6.0) and incubated for 20 minutes at
95uC in order to denature the proteins. Three washes with PBS
were performed for 2 minutes and slices were later blocked with
PBS-BSA 5%.
Precipitation with aptamers
Precipitation of PTEN. The cerebellum homogenate was
divided into 500 ml aliquots. To prevent the unspecific interaction
between protein and aptamers, 12 mg of fragmented salmon sperm
was added to each aliquot. The mixture was transferred to a tube
that contained the equivalent to 150 ml of Streptavidin-magnetic
microspheres (Streptavidin MagneSphere Paramagnetic Particles,
Promega, WI, USA) in order to absorb the nonspecific proteins.
After incubating the mixture for 30 minutes at room temperature
with gentle agitation, the magnetic particles were removed. The
supernatants were incubated with the synthetic aptamers:
PTENz7, 250 nM; PTENz14, 250 nM and Anp32a (250 nM),
or lysozyme reverse aptamers as negative controls. The
PTEN Conformation in Nucleus
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mixture and incubated for 1 hour at room temperature with gentle
agitation. The microspheres were separated from the homogenate
mixture and washed with 500 ml of RIPA (1:2) for 5 minutes, then
washed twice with PBS. The proteins retained by the aptamers
were recovered with 10 ml of NaOH 0.15 M and immediately
neutralized with 10 ml of HCl 0.15 M. The proteins obtained were
used in western blot assays by means of goat antibodies against the
amino terminal of PTEN (sc-6818, Santa Cruz Biotech., CA,
USA).
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